Executive Summary
Antibody-Drug Conjugates (ADCs) represent a revolutionary approach in cancer treatment by combining the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. However, the unique complexity of ADCs — comprising an antibody, a linker, and a cytotoxic payload—introduces a range of analytical challenges.
Continue reading by completing the form below.
